Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.

Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M, Martin R, Montalban X.

Arch Neurol. 2009 Aug;66(8):972-8. doi: 10.1001/archneurol.2009.150.

PMID:
19667218
2.

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

Byun E, Caillier SJ, Montalban X, Villoslada P, Fernández O, Brassat D, Comabella M, Wang J, Barcellos LF, Baranzini SE, Oksenberg JR.

Arch Neurol. 2008 Mar;65(3):337-44. doi: 10.1001/archneurol.2008.47. Epub 2008 Jan 14.

PMID:
18195134
3.

Glypican 5 is an interferon-beta response gene: a replication study.

Cénit MD, Blanco-Kelly F, de las Heras V, Bartolomé M, de la Concha EG, Urcelay E, Arroyo R, Martínez A.

Mult Scler. 2009 Aug;15(8):913-7. doi: 10.1177/1352458509106509. Epub 2009 Jun 25.

PMID:
19556317
4.

Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.

Weinstock-Guttman B, Tamaño-Blanco M, Bhasi K, Zivadinov R, Ramanathan M.

J Neuroimmunol. 2007 Jan;182(1-2):236-9. Epub 2006 Nov 27.

PMID:
17126411
5.

IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.

Leyva L, Fernández O, Fedetz M, Blanco E, Fernández VE, Oliver B, León A, Pinto-Medel MJ, Mayorga C, Guerrero M, Luque G, Alcina A, Matesanz F.

J Neuroimmunol. 2005 Jun;163(1-2):165-71. Epub 2005 Apr 22.

PMID:
15885318
6.

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.

Weber F, Cepok S, Wolf C, Berthele A, Uhr M, Bettecken T, Buck D, Hartung HP, Holsboer F, Müller-Myhsok B, Hemmer B.

Pharmacogenomics J. 2012 Jun;12(3):238-45. doi: 10.1038/tpj.2011.14. Epub 2011 Apr 19.

PMID:
21502966
7.

HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis.

Comabella M, Fernández-Arquero M, Río J, Guinea A, Fernández M, Cenit MC, de la Concha EG, Montalban X.

J Neuroimmunol. 2009 May 29;210(1-2):116-9. doi: 10.1016/j.jneuroim.2009.01.012. Epub 2009 Apr 5. Erratum in: J Neuroimmunol. 2009 Sep 29;214(1-2):132.

PMID:
19349081
8.

Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.

Fainardi E, Rizzo R, Melchiorri L, Castellazzi M, Govoni V, Caniatti L, Paolino E, Tola MR, Granieri E, Baricordi OR.

J Neuroimmunol. 2004 Mar;148(1-2):206-11.

PMID:
14975603
9.

Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.

Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.

Neurol Sci. 2005 Dec;26 Suppl 4:S174-8.

PMID:
16388353
10.

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.

Pereira VC, Malfetano FR, Meira ID, Souza LF, Liem AM, Maiolino A, Alves-Leon SV.

Arq Neuropsiquiatr. 2012 Oct;70(10):774-9.

11.

Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?

van Boxel-Dezaire AH, van Trigt-Hoff SC, Killestein J, Schrijver HM, van Houwelingen JC, Polman CH, Nagelkerken L.

Ann Neurol. 2000 Sep;48(3):313-22.

PMID:
10976637
12.

Clinical characteristics of responders to interferon therapy for relapsing MS.

Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S, Renoux C, Confavreux C.

Neurology. 2003 Jul 22;61(2):184-9. Review.

PMID:
12874396
13.

Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients.

Enevold C, Oturai AB, Sørensen PS, Ryder LP, Koch-Henriksen N, Bendtzen K.

Mult Scler. 2010 Aug;16(8):942-9. doi: 10.1177/1352458510373264. Epub 2010 Jul 1.

PMID:
20595247
14.

Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.

Vosslamber S, van der Voort LF, van den Elskamp IJ, Heijmans R, Aubin C, Uitdehaag BM, Crusius JB, van der Pouw Kraan TC, Comabella M, Montalban X, Hafler DA, De Jager PL, Killestein J, Polman CH, Verweij CL.

Genes Immun. 2011 Sep;12(6):466-72. doi: 10.1038/gene.2011.18. Epub 2011 Apr 7. Erratum in: Genes Immun. 2012 Jul, 13(5):443. van der PouwKraan, T C T M [corrected to van der Pouw Kraan, TCTM].

PMID:
21471993
15.

Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.

Qu ZX, Pliskin N, Jensen MW, White D, Arnason BG.

Arch Neurol. 2001 Jan;58(1):87-90.

PMID:
11176940
16.

Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-β treatment.

Malhotra S, Morcillo-Suárez C, Nurtdinov R, Rio J, Sarro E, Moreno M, Castilló J, Navarro A, Montalban X, Comabella M.

Eur J Neurol. 2013 Oct;20(10):1390-7. doi: 10.1111/ene.12193. Epub 2013 May 22.

PMID:
23700969
17.

IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis.

Malhotra S, Morcillo-Suárez C, Brassat D, Goertsches R, Lechner-Scott J, Urcelay E, Fernández O, Drulovic J, García-Merino A, Martinelli Boneschi F, Chan A, Vandenbroeck K, Navarro A, Bustamante MF, Río J, Akkad DA, Giacalone G, Sánchez AJ, Leyva L, Alvarez-Lafuente R, Zettl UK, Oksenberg J, Montalban X, Comabella M.

J Neuroimmunol. 2011 Oct 28;239(1-2):101-4. doi: 10.1016/j.jneuroim.2011.08.004. Epub 2011 Sep 1.

PMID:
21889215
18.

Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.

Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, Comabella M, Montalban X.

Ann Neurol. 2006 Feb;59(2):344-52.

PMID:
16437558
19.

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, Edan G.

J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):52-6. Epub 2007 Sep 10.

PMID:
17846110
20.

Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.

Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.

Clin Ther. 2010 Jun;32(6):1061-6. doi: 10.1016/j.clinthera.2010.06.005.

PMID:
20637960

Supplemental Content

Support Center